nurix logo
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Partners
  • Platform
    • DELigase
    • Targeted Protein Modulation
    • Targeted Protein Degradation
    • Targeted Protein Elevation
    • Degrader-Antibody Conjugates
  • Pipeline
    • Pipeline
    • Hematology-Oncology
    • Immuno-Oncology
    • Inflammation
  • Scientific Resources
    • Posters & Presentations
    • Videos
    • Mechanisms of Action
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Information
    • Corporate Governance
    • FAQs
  • Careers & Culture
  • Job Openings
  • Contact
Presentations

NX-1607, a small molecule inhibitor of CBL-B, is efficacious as a single agent and in combination with Rituximab in preclinical mouse models of lymphoma

Presentations

Targeted Protein Degraders for the Treatment of Hematologic Malignancies: Addressing the Mutational Resistance of BTK in the Clinic

Presentations

First Disclosure of NX-5948, an Oral Targeted Degrader of Bruton’s Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies

Presentations

Targeted Protein Degradation for Treatment of Hematologic Malignancies Addressing Both the Enzymatic and Scaffolding Functions of BTK Using NX-5948 and NX-2127 in the Clinic

Presentations

Proof of concept of NX-2127, a first-in-class Bruton’s Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with DLBCL

Presentations

BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Preclinical Proof of Concept Studies in Intracranial Patient-Derived Model

Presentations

Drug-resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation

Presentations

Robust Bruton’s tyrosine kinase (BTK) degradation with NX-5948, an oral BTK degrader, in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies

Presentations

Deploying Affinity Selection Mass Spectrometry (ASMS) for Rapid and Flexible Hit Confirmation of DNA-Encoded Library (DEL) Screening in Targeted Protein Modulation (TPM)

Presentations

Discovery and development of targeted protein modulators for the treatment of hematologic malignancies and solid tumors 

nurix logo

 ©2023 Nurix Therapeutics, Inc.

Explore

  • About
  • Platform
  • Pipeline
  • Scientific Resources
  • Clinical Trials
  • Investors
  • Careers & Culture
  • Job Openings
  • Contact

Contact

1700 Owens Street, Suite 205
San Francisco, CA 94158

Direct: 415-660-5320
Fax: 415-525-4200

info@nurix-inc.com

  

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
MENU logo'
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Partners
  • Platform
    • DELigase
    • Targeted Protein Modulation
    • Targeted Protein Degradation
    • Targeted Protein Elevation
    • Degrader-Antibody Conjugates
  • Pipeline
    • Pipeline
    • Hematology-Oncology
    • Immuno-Oncology
    • Inflammation
  • Scientific Resources
    • Posters & Presentations
    • Videos
    • Mechanisms of Action
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Information
    • Corporate Governance
    • FAQs
  • Careers & Culture
  • Job Openings
  • Contact